Drotaverine HCl was shown to provide significant improvement ( P < 0.01 ) in global relief in abdominal pain as perceived by the patient ( 85.9 % vs 39.5 % ) and the clinician ( 82.4 % vs 36.5 % ) in the drotaverine group as compared with placebo .